Stock 2395 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Shin Nippon Biomedical Laboratories, Ltd.

Equities

2395

JP3379950003

Biotechnology & Medical Research

Delayed Japan Exchange
Other stock markets
 07:00:00 26/04/2024 BST 		5-day change 1st Jan Change
1,502 JPY +1.49% Intraday chart for Shin Nippon Biomedical Laboratories, Ltd. +5.55% -11.54%
02-02 Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 CI
01-18 Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval MT

Business Summary

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.

Number of employees: 1,344

Sales per Business

JPY in Million2022Weight2023Weight Delta
Contract Research Organization
95.4 %
16,944 95.5 % 23,924 95.4 % +41.20%
Medipolis
2.4 %
528 3.0 % 601 2.4 % +13.79%
Other
2.2 %
264 1.5 % 549 2.2 % +107.67%
Translational Research
0.1 %
12 0.1 % 16 0.1 % +36.63%

Sales per region

JPY in Million2022Weight2023Weight Delta
Japan
73.8 %
14,657 82.6 % 18,515 73.8 % +26.32%
United States
15.3 %
1,934 10.9 % 3,843 15.3 % +98.76%
Other
10.9 %
1,158 6.5 % 2,733 10.9 % +136.03%

Managers

Managers TitleAgeSince
Ryoichi Nagata CEO
 Chief Executive Officer 65 31/08/81
Shinji Nitanda DFI
 Director of Finance/CFO 55 30/04/02
Terumasa Hirai CMP
 Compliance Officer - 31/03/84
Shunji Haruta CTO
 Chief Tech/Sci/R&D Officer - 31/03/01
Ken Takanashi COO
 Chief Operating Officer 59 30/11/02
Ichiro Nagata BRD
 Director/Board Member 38 31/03/17
Kyomi Nagatoshi IRC
 Investor Relations Contact - 31/01/02
Hiroyuki Izumi PRN
 Corporate Officer/Principal - 31/03/92
Masakazu Suda AUD
 Comptroller/Controller/Auditor 62 31/07/90
Toshihiko Makino AUD
 Comptroller/Controller/Auditor - 31/03/05

Members of the board

Members of the board TitleAgeSince
Ichiro Nagata BRD
 Director/Board Member 38 31/03/17
Shuichi Kanazashi SAM
 Sales & Marketing 64 31/10/02
Ken Takanashi COO
 Chief Operating Officer 59 30/11/02
Satoshi Matsumoto PRN
 Corporate Officer/Principal 56 31/05/99
Shinji Nitanda DFI
 Director of Finance/CFO 55 30/04/02
Hideshi Tsusaki PRN
 Corporate Officer/Principal 57 31/03/96
Shinichi Fukumoto BRD
 Director/Board Member 65 31/05/15
Takashi Yamashita BRD
 Director/Board Member 68 31/05/15
Tsuyoshi Hanada BRD
 Director/Board Member - 25/06/20
Keiko Toya BRD
 Director/Board Member 60 31/05/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 41,632,400 20,315,331 ( 48.80 %) 469 ( 0.001127 %) 48.80 %

Shareholders

NameEquities%Valuation
Nagata Family
37.87 %
15,764,600 37.87 % 158 M ¥
Takahisa Nagata
4.876 %
2,030,000 4.876 % 20 M ¥
Asset Management One Co., Ltd.
3.930 %
1,636,100 3.930 % 16 M ¥
Medipolis Medical Research Institute
3.541 %
1,474,000 3.541 % 15 M ¥
Ikue Nagata
2.460 %
1,024,000 2.460 % 10 M ¥
Rie Umehara
2.460 %
1,024,000 2.460 % 10 M ¥
KYUSHU FINANCIAL GROUP,INC.
2.402 %
1,000,000 2.402 % 10 M ¥
Goldman Sachs Asset Management Co., Ltd. (Japan)
0.9730 %
405,100 0.9730 % 4 M ¥
Deutsche Asset Management (Japan) Ltd.
0.5440 %
226,500 0.5440 % 2 M ¥
Goldman Sachs Asset Management BV
0.1506 %
62,697 0.1506 % 628 855 ¥

Holdings

NameEquities%Valuation
WAVE LIFE SCIENCES LTD.
100.00%
 3,901,348 100.00% 24,071,317 $
TMS CO., LTD.
3.56%
 1,433,320 3.56% 2,661,231 $
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
0.00%
 400 0.00% 4,012 $

Company contact information

Shin Nippon Biomedical Laboratories, Ltd.

St. Luke's Tower, 28/F 8-1 Akashi-cho

104-0044, Tokyo

+81 9 9294 3389

http://www.snbl.co.jp
address Shin Nippon Biomedical Laboratories, Ltd.(2395)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for Shin Nippon Biomedical Laboratories, Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1,502 JPY
Average target price
3,150 JPY
Spread / Average Target
+109.72%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. Stock Shin Nippon Biomedical Laboratories, Ltd.
-11.54% 397M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 2395 Stock
  4. Company Shin Nippon Biomedical Laboratories, Ltd.